eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img


ELIQUIS (apixaban) has demonstrated superior efficacy with a comparable bleeding rate vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total knee replacement surgery1

* Patients received ELIQUIS 2.5 mg BD started 12–24 hours after surgery, and enoxaparin-matching placebo injections OD.1

Patients received subcutaneous enoxaparin 40 mg OD started 12 hours before operation, and ELIQUIS-matching placebo tablets BD.1


ELIQUIS is also available for your patients with acute DVT / PE2

View information to assist your daily practice, including adverse reactions, contraindications and interactions

Access further resources, including treatment guidelines, patient materials and downloadable supporting materials

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ADVANCE-2 = Apixaban Dosed Orally Versus Anticoagulation with Enoxaparin 2   
ARR = Absolute Risk Ratio   
BD = Twice Daily   
DVT = Deep Vein Thrombosis   
LMWH = Low Molecular Weight Heparin   
OD = Once Daily   
PE = Pulmonary Embolism   
RR = Relative Risk   
SC = Subcutaneous   
VTE = Venous Thromboembolic Events

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.2 This is a decision for the prescribing clinician together with patient involvement in the decision-making.


  1. Lassen MR et al. Lancet 2010; 375: 807–815.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.